Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity

Leukemia. 2007 Jun;21(6):1310-2. doi: 10.1038/sj.leu.2404632. Epub 2007 Mar 1.
No abstract available

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Acute Disease
  • Aged
  • Aged, 80 and over
  • Angiogenesis Inhibitors / administration & dosage
  • Angiogenesis Inhibitors / pharmacokinetics
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Humans
  • Leukemia, Myeloid / drug therapy*
  • Middle Aged
  • Recurrence
  • Salvage Therapy / methods
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A / drug effects*

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab